Mustang Bio Announces Rare Pediatric Disease Designation for MB-207 for the Treatment of X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients Aug 31, 2020
Fortress Biotech Announces Positive Topline Clinical Efficacy Results for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease Aug 28, 2020
Mustang Bio Announces Rare Pediatric Disease Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency Aug 17, 2020
Checkpoint Therapeutics to Present at Virtual Corporate Access Summit Hosted by B. Riley FBR on Wednesday, August 19, 2020 Aug 17, 2020
Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights Aug 14, 2020
Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley FBR on Tuesday, August 18 and Wednesday, August 19, 2020 Aug 12, 2020
Fortress Biotech Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights Aug 10, 2020
